- GBI & PARTNERS
- UCB’s epilepsy treatment Briviact enters Brazil under alias
UCB’s epilepsy treatment Briviact enters Brazil under alias
GBI analysis shows that Brazil’s National Health Surveillance Agency (ANVISA) last week nodded Belgium-based UCB Pharma’s Brivlera (brivaracetam). The tablets are indicated as adjunctive therapy in the treatment of partial-onset seizures in patients with epilepsy.
Although Brivlera’s mechanism of action is not fully understood, it seems to involve synaptic vesicle protein 2A (SV2A), which is located in neurons and endocrine cells. Because this transmembrane protein is known to modulate the release of neurotransmitters from one signalling cell to another, it is believed that the drug’s high and selective affinity for SV2A is responsible for its anticonvulsant activity.
GBI analysis reveals that Brivlera is currently registered under the brand name Briviact in Colombia and Mexico, as well as in Argentina, where it obtained approval only after Argentina-based laboratory Monte Verde’s generic version Brivaxon, as GBI reported. In addition, Monte Verde’s product dominates the Peru market.